This site is intended for health professionals only

Wednesday 24 April 2019
LatestNews
Share |

Latest News

Blood samples to help select the right early phase clinical trials for cancer patients

Tuesday 23rd April 2019

Scientists could help match cancer patients with no other treatment options to clinical trials with experimental medicines, by analysing the genetic faults in a sample of their blood, according to research published in Nature Medicine.

The researchers, funded by Cancer Research UK, The Christie Charity, AstraZeneca and the NIHR Manchester Biomedical Research Centre (BRC), demonstrated in their feasibility study that a blood test can be carried out and...

Wed, 12 Dec 2018
The Government has chosen England’s chief pharmacist to look into ‘problematic’ overprescribing in the NHS, it has announced.
Tue, 11 Dec 2018
A no-deal Brexit could create disruption over importing and exporting medicines at the Anglo-French border for up to six months, the Government has predicted.
Tue, 11 Dec 2018
The prospective RCT evaluated patients who underwent a bilateral breast reduction mammoplasty and demonstrated a significant reduction in wound healing complications within 21 days of surgery when treated with PICO versus standard care
Mon, 10 Dec 2018
The Joint Cancer Research UK - AstraZeneca Functional Genomics Centre will be a dedicated world-class resource for AstraZeneca and Cancer Research UK’s academics and alliance partners working at all stages of translational research, from target discovery and validation, to assessing novel drug combinations
Fri, 7 Dec 2018
Novartis's BYL719 is in late-stage development, and Qiagen expects to provide its companion diagnostic to clinical laboratory partners who will then be ready to offer immediate access to the test upon potential regulatory approvals
Thu, 6 Dec 2018
Leading academics and health data specialists have formed an alliance to boost science and innovation in the UK
Thu, 6 Dec 2018
Delays in taking new cancer drugs through clinical trials and getting them approved for use mean NHS patients are waiting longer to access them, a report by the Institute of Cancer Research (ICR) finds.